Anebulo Pharmaceuticals (NASDAQ:ANEB) Announces Quarterly Earnings Results

Anebulo Pharmaceuticals (NASDAQ:ANEB) issued its earnings results on Wednesday. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.08, Yahoo Finance reports.

Anebulo Pharmaceuticals Stock Performance

Shares of Anebulo Pharmaceuticals stock traded up $0.09 on Friday, hitting $2.05. The stock had a trading volume of 9,487 shares, compared to its average volume of 6,878. The stock has a 50 day moving average of $2.05 and a 200 day moving average of $2.35. Anebulo Pharmaceuticals has a twelve month low of $1.62 and a twelve month high of $3.61. The firm has a market capitalization of $53.16 million, a P/E ratio of -5.68 and a beta of -1.01.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.